E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with spastic brain lesions.
Children with cerebral palsy (CP) and in the hemiplegic adult. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with spastic brain lesions.
Children with cerebral palsy (CP) and in the hemiplegic adult. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. Demonstrate that repeated injections of high-dose botulinum toxin significantly improve the functional functioning of hemiplegic spastic adult patients compared to single-dose, moderate-dose injections.
2. Demonstrate the validity of the low-cost KI-Gait walk analysis system, based on the Kinect infrared camera device, in children with cerebral palsy (CP) and in hemiplegic adults.
Demonstrate that repeated injections of high-dose botulinum toxin significantly improve the functional functioning of hemiplegic spastic patients compared to single-dose, moderate-dose injections
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Demonstrate the validity of the low-cost KI-Gait walk analysis system, based on the Kinect infrared camera device, in children with cerebral palsy (CP) and in hemiplegic adults. |
|
E.3 | Principal inclusion criteria |
1. adults (> 18 years)
2.hemiparesis after first stroke, delay after stroke> 6 months
3. limb-gait spasticity
4.ability to perform treadmill walking tests, indication of focal chemical denervation
Sub-study :
1. old: > 4 and <18 years,
2.cerebral palsy (spastic hemiplegia, diplegia or quadriplegia)
3. Gross Motor Function Classification System (GMFCS) <4. |
|
E.4 | Principal exclusion criteria |
1. aphasia or major cognitive impairment limiting functional evaluation
2. neurological or orthopedic problem interfering with the function of the lower limb studied
3. injections of botulinum toxin in the lower limb less than 5 months old
4.contraindication to botulinum toxin (neuromuscular disease under -cente)
5.contraindication to performing an MRI.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Functional assessments will be based on the WHO International Classification of Functioning, Disability and Health.
Assessment by clinical exam and by NMR |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The evaluations will be done at Mont 1, month 3 and month 6. |
|
E.5.2 | Secondary end point(s) |
Impairments will be assessed using clinical examination (evaluation of range of motion by manual goniometry, spasticity by modified Ashworth and Tardieu scales, evaluation of motor control by the Fugl-Meyer test), by functional data (10-meter fast-running speed, modified 6-minute test22, timed rise and fall test, 23 Timed Up and Go Test24) and AQM. Activity limitations will be assessed using the ABILOCO25 questionnaire. The quality of life of patients will be evaluated by the French version of Short-Form Health Survey SF-36. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The evaluations will be done at Mont 1, month 3, month 4, month 6 and month 7. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
After the visit dont at month 7. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |